Cor
Executive Summary
Sales of GP IIb/IIIa antagonist Integrilin (eptifibatide) reported by Schering-Plough to Cor increased 35% to $11.3 mil. for the quarter, the biotech company said. Cor recorded $5.7 mil. in co-promotion revenue related to Integrilin